TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04194255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 15 g GOS
Description: iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
Study: NCT04194255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 15 g FOS
Description: iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labelled iron as ferrous fumarate + 15 g acacia gum
Description: iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
Study: NCT02812277

Intervention type: OTHER
Description: This is a Non-Interventional Study, so there are no drug or devices included.
Study: NCT05386615

Intervention type: DEVICE
Intervention: Body System - Functional
Description: MR-Guided Focused Ultrasound
Study: NCT02681237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Poly (ADP-ribose) polymerase (PARP) inhibitor.
Study: NCT00710528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL-101
Description: CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
Study: NCT03770585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided Facet joint injection
Description: Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
Study: NCT00509145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod 0.6 mg capsule, oral, once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, once daily, capsule
Study: NCT01608932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring for frail patients with chronic diseases
Description: Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms.
Study: NCT04181125

Intervention type: OTHER
Intervention: Biodex Balance System
Description: For the computerized evaluation of postural control, Biodex Balance System will be used.
Study: NCT03770585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrsound guided Facet joint injection
Description: Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
Study: NCT04181125

Intervention type: OTHER
Intervention: Biodex Balance System
Description: For the computerized evaluation of postural control, Biodex Balance System will be used.

Intervention type: OTHER
Intervention: Balance Error Scoring System (BESS)
Description: For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.

Intervention type: OTHER
Intervention: Balance Error Scoring System (BESS)
Description: For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
Study: NCT01324401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut flour OIT
Description: Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
Study: NCT04696614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise
Study: NCT00101452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl-l-methionine
Description: 1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules look like escitalopram capsules and SAMe capsules
Study: NCT04021693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handheld Ultrasound Devices
Description: Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
Study: NCT03853278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: colorectal cancer self-management
Description: The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
Study: NCT04696432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prizloncabtagene autoleucel
Description: Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Study: NCT03767790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAPS
Description: The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
Study: NCT03292172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
Study: NCT02901678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrusion by 400 g
Description: using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrusion by 400 g
Description: using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
Study: NCT02033564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh/Miller Laryngoscope
Study: NCT01281332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menopod
Description: The mechanism of action of the device will not be revealed in advance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive device
Study: NCT00357279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denufosol tetrasodium (INS37217) Inhalation Solution
Description: Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - 0.9% w/v sodium chloride solution
Description: 4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
Study: NCT02033564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Laryngoscope
Study: NCT02152956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study: NCT02018731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Metformin & L-Citrulline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline and Metformin & L-Citrulline
Study: NCT02601339

Intervention type: PROCEDURE
Intervention: ETV/CPC
Description: endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus

Intervention type: PROCEDURE
Intervention: ETV/CPC
Description: endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
Study: NCT02152956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral inhibitor of JAK kinase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study: NCT02369744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silodosin
Description: 8mg tablet, 1 tab PO daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg Tab, 1 tab PO daily for 2 weeks
Study: NCT03241147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single dose, 10 mg film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single dose, 10 mg film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single dose, 10 mg film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single dose, 10 mg film coated tablet
Study: NCT04521049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
Study: NCT03269708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education regarding telomere length
Description: Teaching concepts of cellular aging and telomere length
Study: NCT00710073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sono-electro-magnetic therapy (Sonodyn Medico Star)
Description: twice a day for 10 minutes during 6 or 12 weeks
Study: NCT05307029

Intervention type: PROCEDURE
Intervention: rehabilitation with fixed full-arch prosthesis

Intervention type: PROCEDURE
Intervention: rehabilitation with fixed full-arch prosthesis
Study: NCT02177201

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group 1
Description: Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
Study: NCT00894556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan
Description: Single dose of 10 mg orally disintegrating tablet at onset of migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan
Description: Single dose of 10 mg orally disintegrating tablet at onset of migraine attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan
Description: Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
Study: NCT01388985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Diploid Cell Vaccine (HDCV) rabies vaccine
Description: Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Diploid Cell Vaccine (HDCV) rabies vaccine
Description: Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
Study: NCT02202083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cook Balloon
Description: There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6.
Study: NCT01519167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.1 - 1.0 mcg/kg/hr IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.025 - 2 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.5 - 3 mcg/kg IV
Study: NCT01643096

Intervention type: OTHER
Group type: OTHER
Intervention: Zataria multiflora Boiss
Description: Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
Study: NCT00894556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Sumatriptan
Description: single dose of generic sumatriptan 100 mg at onset of migraine attack
Study: NCT02860312

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradialytic exercise on stationary bicycles
Description: Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
Study: NCT01643096

Intervention type: OTHER
Group type: OTHER
Intervention: Sumac
Description: Thermic effect of food of Sumac and comparison between hot and cold temperament people
Study: NCT02860312

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-exercising group
Description: Patients are having their usual physical activity
Study: NCT04119466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing training
Description: The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing training
Description: The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
Study: NCT03366519

Intervention type: PROCEDURE
Intervention: clinical echography (CE)
Description: clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
Study: NCT03787498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: Tablets
Study: NCT02200640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Micardis®, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Micardis®, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of COZAAR®, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of COZAAR®, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00645957

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: penrose drain
Description: incision and drainage of the infection with placement of a penrose drain
Study: NCT04371393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
Study: NCT00571168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emend
Description: 125 mg/d on day 1; 80 mg/d on day 2-4